Oramed Pharmaceuticals Inc. — Major Shareholding Notification 2021

Sep 2, 2021

FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
--------	--------------------------------------------------

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Silberman David				ORMP ]	2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify
(Last)	20 MAMILLA AVENUE	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 09/01/2021							X below) below) Chief Financial Officer
(Street) JERUSALEM L3 9414904 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date					2A. Deemed	3.					5. Amount of Securities Beneficially Owned Following
				(Month/Day/Year)		Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)				6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
							Code V		Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock(1)				09/01/2021(2)			A		50,000	A	\$0	50,000	D
						Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Year)	if any (Month/Day/Year)	Code (Instr. 8)	Derivative (Month/Day/Year) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Underlying Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$20.19	09/01/2021		A	50,000		(3)	09/01/2031 Common	Stock	50,000	\$0	50,000	D

Explanation of Responses:

1. Represents common stock underlying Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. The RSUs will vest as follows: 33,333 shall vest in three equal installments over a period of three years upon Issuer's common stock achieving a specified price per share, and 16,667 shall vest in three equal installments over a period of three years upon Issuer's achievement of certain business objectives.

3. The Stock Options will vest in four equal installments of 12,500 on each of June 27, 2022, June 27, 2023, June 27, 2024 and June 27, 2025.

/s/ David Silberman 09/02/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.